Beyond Quality of Life: Is TTVR Finally Moving the Needle on Mortality?

For years, the conversation around transcatheter tricuspid valve replacement (TTVR) has been defined by a significant caveat: we can make patients feel better, but can we help them live longer? Data from the TRISCEND II trial, recently presented at ACC 2026, suggests the tide may be turning.

While initial approvals for devices like Evoque were rooted in dramatic improvements in health status and KCCQ scores, the 2-year data now offers "provocative" hints of a survival benefit.

The 2-Year Snapshot: TRISCEND II

The trial randomized patients with symptomatic, severe tricuspid regurgitation (TR) to TTVR plus optimal medical therapy (OMT) versus OMT alone.

• TR Reduction: The efficacy remains undisputed. At 2 years, approximately 95% of TTVR and crossover patients maintained TR grades of mild or less.

• The Mortality Signal: In a landmark analysis at one year, patients who did not cross over to TTVR had a significantly higher rate of all-cause mortality (44.9%) compared to those in the TTVR group (19.1%).

• Quality of Life: The KCCQ-OS improvement was sustained, showing a nearly 18-point jump in the TTVR group compared to negligible gains in the OMT-only cohort.

The "Pacemaker" Problem

It wasn't all clear skies. The data highlighted a cumulative pacemaker rate of 19.7% in the TTVR cohort at 2 years, compared to just 9.0% in the control group. For the "forgotten valve," the price of a dry annulus often remains a conduction disturbance—a factor that remains a critical part of the heart team discussion.

Clinical Takeaway

We are moving from a "symptom-relief" mindset to a "disease-modifying" one. While these 2-year results are hypothesis-generating due to small sample sizes and high crossover rates, they reinforce a fundamental surgical truth: TR is not a benign bystander. As we refine patient selection, the choice between repair and replacement will increasingly hinge on balancing the immediate safety of edge-to-edge repair against the definitive (and potentially life-extending) TR elimination provided by replacement.

---

What are your thoughts on the 20% pacemaker risk? Is it a fair trade for a 25% absolute reduction in mortality?

Article inspired by recent findings presented at the American College of Cardiology 2026 Scientific Session.